Coronary Heart Disease | NT-proCNP levels predict higher atherosclerotic cardiovascular risk profile in patients with proliferative diabetic retinopathy | springermedicine.com

Springer Medicine

Top

Acta Diabetologica

Published in:

21-04-2023 | Coronary Heart Disease | Original Article

NT-proCNP levels predict higher atherosclerotic cardiovascular risk profile in patients with proliferative diabetic retinopathy

Authors: Cebrail Karaca, Murat Bektas, Mevlut T. Dincer, Oguz K. Bakkaloglu, Zafer Cebeci, Alev Bakir, Nurhan Seyahi, Sinan Trabulus, Tufan Tukek

Published in: Acta Diabetologica | Issue 8/2023

Login to get access

Abstract

Aims

In this study, we aimed to demonstrate the effectiveness of serum amino-terminal proCNP (NT-proCNP) levels in predicting coronary heart disease (CHD) and cardiovascular risk in type 2 diabetes mellitus (T2DM) patients.

Methods

We recruited 73 patients with T2DM in the study. Additionally, we grouped the patients according to their status of diabetic retinopathy (DR) as no DR, non-proliferative DR, or proliferative DR. Serum NT-proCNP levels of the patients were measured and their atherosclerotic cardiovascular disease (ASCVD) risk scores were calculated.

Results

There was no significant difference in terms of NT-proCNP levels between the groups (p = 0.3) and in terms of CHD and ASCVD risk scores (p = 0.4 and p = 0.4, respectively). In the correlation analysis, a significant correlation was observed between the NT-proCNP levels and the ASCVD risk score (r = 0.373; p = 0.008 among the entire cohort and r = 0.555; p = 0.01 in the non-proliferative-DR group), smoking status (r = 0.280; p = 0.03 among the entire cohort and r = 0.362; p = 0.035 in the non-proliferative-DR group), sBP (r = 0.278; p = 0.038 among the entire cohort), and dBP (r = 0.284; p = 0.034 among the entire cohort and r = 0.482; p = 0.004 in the proliferative-DR group). In the ROC analysis, we found that the NT-proCNP level predicted a high ASCVD risk score with 83.3% sensitivity and 70.8% specificity and a very high ASCVD risk score with 100% sensitivity and 69.2% specificity among the proliferative-DR patients. No cut-off value was calculated for the prediction of high and very-high ASCVD risk scores in patients with non-proliferative DR. Similarly, no cut-off value was revealed for the prediction of established coronary artery disease in all groups.

Conclusions

Our study revealed a significant association between NT-proCNP levels and high ASCVD risk scores in patients with proliferative DR.

1.

Sellitti DF, Koles N, Mendonca MC (2011) Regulation of C-type natriuretic peptide expression. Peptides 32(9):1964–1971. https://doi.org/10.1016/j.peptides.2011.07.013CrossRefPubMed

2.

Palmer SC, Prickett TC, Espiner EA, Yandle TG, Richards AM (2009) Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension 54(3):612–618. https://doi.org/10.1161/HYPERTENSIONAHA.109.135608CrossRefPubMed

3.

Manfra O, Calamera G, Froese A, Arunthavarajah D, Surdo NC, Meier S et al (2022) CNP regulates cardiac contractility and increases cGMP near both SERCA and TnI: difference from BNP visualized by targeted cGMP biosensors. Cardiovasc Res 118(6):1506–1519. https://doi.org/10.1093/cvr/cvab167CrossRefPubMed

4.

Prickett TC, Yandle TG, Nicholls MG, Espiner EA, Richards AM (2001) Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun 286(3):513–517. https://doi.org/10.1006/bbrc.2001.5419CrossRefPubMed

5.

Iglicki M, Loewenstein A, Barak A, Schwartz S, Zur D (2020) Outer retinal hyperreflective deposits (ORYD): a new OCT feature in naive diabetic macular oedema after PPV with ILM peeling. Br J Ophthalmol 104(5):666–671. https://doi.org/10.1136/bjophthalmol-2019-314523CrossRefPubMed

6.

Iglicki M, Busch C, Zur D et al (2019) Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the International Retina Group Real-Life 24-Month Multicenter Study. IRGREL-DEX Study Retina 39(1):44–51. https://doi.org/10.1097/IAE.0000000000002196CrossRefPubMed

7.

Iglicki M, Zur D, Busch C, Okada M, Loewenstein A (2018) Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the “DR-Pro-DEX Study.” Acta Diabetol 55(6):541–547. https://doi.org/10.1007/s00592-018-1117-zCrossRefPubMed

8.

Iglicki M, Zur D, Fung A et al (2019) TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasone implant: the Tradition Study. Acta Diabetol 56(10):1141–1147. https://doi.org/10.1007/s00592-019-01357-yCrossRefPubMed

9.

Zur D, Iglicki M, Busch C et al (2018) OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology 125(2):267–275. https://doi.org/10.1016/j.ophtha.2017.08.031CrossRefPubMed

10.

Tang F, Luenam P, Ran AR et al (2021) Detection of diabetic retinopathy from ultra-widefield scanning laser ophthalmoscope images: a multicenter deep learning analysis. Ophthalmol Retina 5(11):1097–1106. https://doi.org/10.1016/j.oret.2021.01.013CrossRefPubMed

11.

Wong TY, Cheung CM, Larsen M, Sharma S, Simo R (2016) Diabetic retinopathy. Nat Rev Dis Primers 2:16012. https://doi.org/10.1038/nrdp.2016.12CrossRefPubMed

12.

No authors listed (2011) Use of Glycated Haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. World Health Organization, Geneva

13.

Goolsby MJ (2002) National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. J Am Acad Nurse Pract 14(6):238–242. https://doi.org/10.1111/j.1745-7599.2002.tb00119.xCrossRefPubMed

14.

Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006CrossRefPubMedPubMedCentral

15.

Piepoli MF, Hoes AW, Agewall S et al (2016) European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37(29):2315–2381. https://doi.org/10.1093/eurheartj/ehw106CrossRefPubMedPubMedCentral

16.

Wilkinson CP, Ferris FL 3rd, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110(9):1677–1682. https://doi.org/10.1016/S0161-6420(03)00475-5CrossRefPubMed

17.

Del Ry S, Maltinti M, Cabiati M, Emdin M, Giannessi D, Morales MA (2008) C-type natriuretic peptide and its relation to non-invasive indices of left ventricular function in patients with chronic heart failure. Peptides 29(1):79–82. https://doi.org/10.1016/j.peptides.2007.10.022CrossRefPubMed

18.

Del Ry S, Cabiati M, Stefano T et al (2011) Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients. Regul Pept 166(1–3):15–20. https://doi.org/10.1016/j.regpep.2010.08.004CrossRefPubMed

19.

Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D et al (2010) Amino-terminal pro-C-type natriuretic peptide is associated with arterial stiffness, endothelial function and early atherosclerosis. Atherosclerosis 211(2):649–655. https://doi.org/10.1016/j.atherosclerosis.2010.03.020CrossRefPubMed

20.

Lok DJ, Klip IT, Voors AA et al (2014) Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail 16(9):958–966. https://doi.org/10.1002/ejhf.140CrossRefPubMed

21.

Prickett TC, Doughty RN, Troughton RW et al (2017) C-Type natriuretic peptides in coronary disease. Clin Chem 63(1):316–324. https://doi.org/10.1373/clinchem.2016.257816CrossRefPubMed

22.

Prickett TCR, Lunt H, Warwick J, Heenan HF, Espiner EA (2019) Urinary amino-terminal Pro-C-Type natriuretic peptide: a novel marker of chronic kidney disease in diabetes. Clin Chem 65(10):1248–1257. https://doi.org/10.1373/clinchem.2019.306910CrossRefPubMed

23.

Prickett TCR, Troughton RW, Espiner EA (2020) Effect of statin therapy on plasma C-type natriuretic peptides and Endothelin-1 in males with and without symptomatic coronary artery disease. Sci Rep 10(1):7927. https://doi.org/10.1038/s41598-020-64795-7CrossRefPubMedPubMedCentral

24.

Frank RN (2004) Diabetic retinopathy. N Engl J Med 350(1):48–58. https://doi.org/10.1056/NEJMra021678CrossRefPubMed

25.

Prickett TC, Olney RC, Cameron VA, Ellis MJ, Richards AM, Espiner EA (2013) Impact of age, phenotype and cardio-renal function on plasma C-type and B-type natriuretic peptide forms in an adult population. Clin Endocrinol (Oxf) 78(5):783–789. https://doi.org/10.1111/cen.12035CrossRefPubMed

26.

Prickett TCR, Darlow BA, Troughton RW et al (2018) New insights into cardiac and vascular natriuretic peptides: findings from young adults born with very low birth weight. Clin Chem 64(2):363–373. https://doi.org/10.1373/clinchem.2017.280354CrossRefPubMed

27.

Prickett TCR, Spittlehouse JK, Miller AL et al (2019) Contrasting signals of cardiovascular health among natriuretic peptides in subjects without heart disease. Sci Rep 9(1):12108. https://doi.org/10.1038/s41598-019-48553-yCrossRefPubMedPubMedCentral

28.

Chun TH, Itoh H, Ogawa Y et al (1997) Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension 29(6):1296–1302. https://doi.org/10.1161/01.hyp.29.6.1296CrossRefPubMed

29.

Marin T, Gongol B, Chen Z et al (2013) Mechanosensitive microRNAs-role in endothelial responses to shear stress and redox state. Free Radic Biol Med 64:61–68. https://doi.org/10.1016/j.freeradbiomed.2013.05.034CrossRefPubMedPubMedCentral

30.

Griffith TM (2004) Endothelium-dependent smooth muscle hyperpolarization: do gap junctions provide a unifying hypothesis? Br J Pharmacol 141(6):881–903. https://doi.org/10.1038/sj.bjp.0705698CrossRefPubMedPubMedCentral

31.

Sangaralingham SJ, McKie PM, Ichiki T et al (2015) Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population. Hypertension (Dallas, Tex: 1979) 65(6):1187–1194. https://doi.org/10.1161/HYPERTENSIONAHA.115.05366

32.

Espiner EA, Prickett TC, Taylor RS, Reid RA, McCowan LM (2015) Effects of pre-eclampsia and fetal growth restriction on C-type natriuretic peptide. BJOG 122(9):1236–1243. https://doi.org/10.1111/1471-0528.13397CrossRefPubMed

33.

Avogaro A, Fadini GP, Gallo A, Pagnin E, de Kreutzenberg S (2006) Endothelial dysfunction in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 16(Suppl 1):S39-45. https://doi.org/10.1016/j.numecd.2005.10.015CrossRefPubMed

34.

Leasher JL, Bourne RR, Flaxman SR et al (2016) Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis From 1990 to 2010. Diabetes Care 39(9):1643–1649. https://doi.org/10.2337/dc15-2171CrossRefPubMed

35.

Iglicki M, Busch C, Lanzetta P et al (2023) Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO-Is there any difference? The VITDEX study. Eye (Lond) 37(2):280–284. https://doi.org/10.1038/s41433-022-01931-9CrossRefPubMed

36.

Hong TC, Yeh HI, Shih BF et al (2006) Brain natriuretic peptide and C-type natriuretic peptide are differently regulated by age but similarly elevated in coronary artery disease. Acta Cardiol 61(1):1–5. https://doi.org/10.2143/AC.61.1.2005133CrossRefPubMed

37.

Roger VL (2007) Epidemiology of myocardial infarction. Med Clin North Am 91(4):537–552; ix. https://doi.org/10.1016/j.mcna.2007.03.007

38.

McCullough PA (2007) Coronary artery disease. Clin J Am Soc Nephrol 2(3):611–616. https://doi.org/10.2215/CJN.03871106CrossRefPubMed

Title: NT-proCNP levels predict higher atherosclerotic cardiovascular risk profile in patients with proliferative diabetic retinopathy
Authors: Cebrail Karaca
Murat Bektas
Mevlut T. Dincer
Oguz K. Bakkaloglu
Zafer Cebeci
Alev Bakir
Nurhan Seyahi
Sinan Trabulus
Tufan Tukek
Publication date: 21-04-2023
Publisher: Springer Milan
Keywords: Coronary Heart Disease
Diabetic Retinopathy
Diabetic Retinopathy
Diabetes
Type 2 Diabetes
Published in: Acta Diabetologica / Issue 8/2023
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-023-02095-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties